28 Nov 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company's portfolio of therapies, encouraging data from the 2022 SITC conference and the outlook for 2023.
25 Nov 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses achieving a key reliability milestone for the company's laser diodes.
23 Nov 2022 - Altech Chemicals Limited (ASX:ATC) CFO Martin Stein discusses the recent joint venture with Fraunhofer IKTS and the CERENERGY solid state sodium alumina battery.
22 Nov 2022 - Radiopharmaceutical Theranostics Limited (ASX:RAD) Managing Director and CEO Riccardo Canevari discusses the progress of the company's brain, lung and prostate cancer therapies.
17 Nov 2022 - Genetic Signatures Limited (ASX:GSS) CEO and Director Dr John Melki discusses the company's technology, business model, 2022 highlights and outlook.
15 Nov 2022 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Dr Michael Baker provides an update on the company.
15 Nov 2022 - OncoSil Medical Limited (ASX:OSL) Non-Executive Director Brian Leedman discusses joining the board of OncoSil and receiving CE mark approval for the company's therapy.
11 Nov 2022 - K2fly Limited (ASX:K2F) CEO Nic Pollock discusses K2F's progress and milestones over the past year.
04 Nov 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses the company's new agreement with Case Western Reserve University.
03 Nov 2022 - Antisense Therapeutics Limited (ASX:ANP) Chair, Dr Charmaine Gittleson, and new Chief Commercial Officer, Dr Anthony Filippis, discuss Antisense's progress, attracting new talent to the company, and what drew Dr Filippis to the role.
